(New York) Pfizer saw sharp declines in first-quarter revenue and profit due to slumping sales of its COVID-19 vaccine and pill, but still beat expectations and stuck to guidance for the year.
The American laboratory saw its turnover plunge by 29% over the period, to 18.3 billion dollars.
Sales of the Comirnaty vaccine developed with the German laboratory BioNTech fell by 77%, weighed down by a sharp drop in orders.
Those of the anti-COVID-19 pill Paxlovid, on the other hand, are up compared to the same period in 2022, in particular due to a last order from the American government before a transition to more traditional marketing, as well as by a strong demand in China due to an upsurge in the pandemic.
Pfizer still expects for 2023 a drop of 64% in its Comirnaty vaccine sales and 58% in its Paxlovid pill sales.
Without these two products, which boosted Pfizer’s financial performance for two years, the laboratory’s turnover increased in the first quarter by 5%.
Its net profit fell 30% to $5.5 billion.
Pfizer still anticipates revenue growth excluding Paxlovid and Cominarty of 7% to 9% over the year.
The laboratory is counting on the arrival on the market of new products, in particular after the recent green lights from the American Medicines Agency (FDA) for a new migraine treatment which has the particularity of being administered by a nasal aerosol (Zavzpret) as well as for the prescription of the eczema drug Cibinqo for adolescents and the pneumococcal infection vaccine Prevnar for children.
The action of the group took 0.7% in electronic trading prior to the opening of the stock market.